General News / Announcements
FDA Inspection results are in!
MedisourceRx is proud to announce that NO observations were made by the FDA during our 2022 inspection of our facility.
This is a rare achievement in an ever-evolving regulatory environment!
MedisourceRx is registered with the DEA, State Board of Pharmacy licensed, and registered with the FDA as a 503B outsourcing facility. As an outsourcing facility, we focus exclusively on sterile products and follow cGMP, GDP and cGLP guidelines.
This dedication to sterile products has led to the development of systems that enhance quality assurance and patient safety. We have proved our dedication with our current inspection by the FDA and BOP that resulted in no Observations. We are proud of the team we have put together and the work we have done. Organizations we work with know they can rely on us to deliver consistently, in all our markets.
UCI to take part in clinical trial of drug for critically ill COVID-19 patients
UCI to take part in clinical trial of drug for critically ill COVID-19 patients. Aviptadil could save people suffering from acute respiratory distress syndrome.
Final Manufacturing Validation of RLF-100
Relief Therapeutics and NeuroRx Announce Final Manufacturing Validation of RLF-100 for Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome.
The I-SPY COVID Trial utilizes Quantum Leap's adaptive platform trial design
NRx Pharmaceuticals and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with ZYESAMIÔ (Aviptadil) in the I-SPY COVID Trial.